Outcomes in Psoriasis Clinical Trials from January 2011 to March 2012

Francesca Sampogna, Damiano Abeni

Research output: Contribution to journalReview articlepeer-review


In clinical trials, conclusions on treatment safety and efficacy depend on the selected outcomes; therefore, it is very important to choose outcomes that are able to address meaningful aspects of the disease experience. This review analyzes 54 clinical trials of psoriasis treatments that took place from January 2011 to March 2012. The majority of the primary outcomes were based exclusively on the clinician/investigator assessment. Twenty-four percent of studies had a patient-reported measure listed as primary outcome. However, of the 34 studies reporting secondary outcomes, only seven had secondary outcomes based exclusively on the clinician/investigator assessment. Although there is a trend toward an increase in trials incorporating patient-reported measures, it is necessary to improve the quality of the measures used, and to adopt more thoroughly validated and homogeneous clinical measures and times of follow-up.

Original languageEnglish
Pages (from-to)137-147
Number of pages11
JournalCurrent Dermatology Reports
Issue number3
Publication statusPublished - Sep 2012


  • Assessment
  • Clinical severity
  • Clinical trials
  • Dermatology
  • Dermatology Life Quality Index
  • DLQI
  • Outcomes
  • Palmoplantar psoriasis
  • PASI
  • PGA
  • Physician's Global Assessment
  • Plaque psoriasis
  • Plaque psoriasis of hands and feet
  • Psoriasis
  • Psoriasis Area and Severity Index
  • Psoriatic arthritis
  • Quality of life
  • Scalp psoriasis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Outcomes in Psoriasis Clinical Trials from January 2011 to March 2012'. Together they form a unique fingerprint.

Cite this